BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Bioventus Inc.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$13.49+0.19 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $955.61M
- P/E (TTM)
- 17.5
- Dividend yield
- –
Bioventus Inc. revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| US Segment | $513.71M | $508.02M | $502.10M | $497.82M | $497.41M | $503.05M | $506.81M | $490.41M | $473.73M | $460.16M | $449.86M | – | 88.3% | +3.3% |
| International Segment | $68.14M | $68.28M | $65.99M | $66.01M | $66.73M | $64.65M | $66.47M | $64.65M | $63.17M | $62.58M | $62.49M | – | 11.7% | +2.1% |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $513.71M | $508.02M | $502.10M | $497.82M | $497.41M | $503.05M | $506.81M | $490.41M | $473.73M | $460.16M | $449.86M | $439.62M | 88.3% | +3.3% |
| International | $68.14M | $68.28M | $65.99M | $66.01M | $66.73M | $64.65M | $66.47M | $64.65M | $63.17M | $62.58M | $62.49M | $63.13M | 11.7% | +2.1% |
From the segment and revenue-disaggregation notes of Bioventus's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.